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Introduction: Histone deacetylase inhibitors (HDACIs) induce
growth arrest and apoptosis in cancer cells. In addition to their
intrinsic anticancer properties, HDACIs modulate cellular responses
to ionizing radiation (IR). We examined the molecular mecha-
nism(s) associated with the radiosensitizing effects of HDACIs in
human lung cancer cells.
Methods: Lung cancer cells were pretreated with the appropriate
concentrations of suberoylanilide hydroxamic acid or trichostatin A.
After 2 hours, cells were irradiated with various doses of -IR, and
then we performed 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide assay, fluorescence-activated cell sorting analysis,
clonogenic assay, and Western blotting to detect cell viability or
apoptosis and changes of specific proteins expression levels.
Results: In this study, we showed that HDACIs (including suberoy-
lanilide hydroxamic acid and trichostatin A) and IR synergistically
trigger cell death in human non-small cell lung cancer cells. Cell
viability and clonogenic survival were markedly decreased in cul-
tures cotreated with HDACIs and IR. Interestingly, p53 acetylation
at lysine 382 was significantly increased, and c-myc expression
simultaneously down-regulated in cotreated cells. Radiosensitiza-
tion by HDACIs was inhibited on transfection with small interfering
RNA against p53 and c-myc overexpression, supporting the involve-
ment of p53 and c-myc in this process. Furthermore, c-myc down-
regulation and apoptotic cell death coinduced by IR and HDACI
were suppressed in cells transfected with mutant K382R p53 and
C135Y p53 displaying loss of acetylation at lysine 382 and DNA-
binding activity, respectively.
Conclusions: Our results collectively demonstrate that the degree of
radiosensitization by HDACIs is influenced by acetyl p53-mediated
c-myc down-regulation.
Key Words: Acetylation, c-myc, HDAC inhibitor, Ionizing
radiation, p53.
(J Thorac Oncol. 2011;6: 1313–1319)
The histone acetylation status is determined by the op-posing actions of histone acetyl transferase (HAT) and
histone deacetylase (HDAC), which lead to alterations in
chromatin structure, and consequently, regulation of gene
expression. The activities of these enzymes are disrupted
in several cancers.1 In particular, aberrant HDAC activity
results in the transcriptional repression of tumor suppres-
sor genes, which is a common event in tumor formation.
Given this molecular finding, HDACIs are considered
promising therapeutic agents for cancer treatment. In a
number of in vitro and in vivo experimental models,
HDACIs induce diverse biological responses in cancer
cells, including apoptosis, cell cycle arrest, and differen-
tiation. These compounds additionally exhibit lower tox-
icity in normal cells and tissues, because aberrant acety-
lation is a characteristic of neoplastic cells.2,3 Although the
molecular events underlying the biological effects of
HDACIs remain to be fully elucidated, recent studies have
demonstrated a direct link between induction of apoptosis
in cancer cells and the therapeutic efficacy of these com-
pounds. In addition, combinations of HDACIs with other
chemotherapeutic drugs and ionizing radiation (IR) have
been shown to exert strong synergistic effects in several
cancer cells, compared with single agents.4–8 The molec-
ular mechanism(s) associated with the radiosensitizing
effects of HDACIs in a broad array of cancer cells remain
to be clarified.
In addition to histones, p53 serves as a substrate of
HAT and HDAC in vitro and in vivo.9–12 p53 is a se-
quence-specific DNA-binding transcription factor that ex-
erts antiproliferative effects, including apoptosis and
growth arrest, in response to various stress factors. Post-
translational modifications, including phosphorylation and
acetylation, play important roles in the stabilization and
activation of p53 in response to stress signals, such as
DNA damage.13 HDACIs impede deacetylation and stabi-
lize the acetylated isoforms of p53.14,15 These results
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suggest that stabilization of acetylated p53 by these com-
pounds is involved in modulation of the expression levels
of different subsets of genes.
In this study, we explored the potential therapeutic
value of a combination of HDACIs, including suberoylanilide
hydroxamic acid (SAHA) and trichostatin A (TSA), with IR
in human lung cancer cells. Moreover, the potential cellular
mechanisms underlying enhanced antitumor activity were
examined. Our data show that site-specific stabilization of
acetylated p53 results in c-myc down-regulation. Experi-
ments performed to evaluate the significance of c-myc re-
pression by p53 demonstrated that ectopic c-myc expression
interferes with the combined therapeutic effects of HDACIs
and IR. On the basis of these results, we propose that
HDACIs sensitize lung cancer cells to IR through acetyl
p53-mediated c-myc down-regulation.
MATERIALS AND METHODS
Cell Cultures and Reagents
A549 and H1299 human non-small cell lung cancer
cells were purchased from the American Type Culture Col-
lection (Manassas, VA) and grown in the recommended
growth medium (Invitrogen, Carlsbad, CA). SAHA and TSA
were purchased from ALEXIS Corporation (Switzerland) and
Sigma-Aldrich (St. Louis, MO), respectively. Antibodies
against acetyl-p53 (Lys 382), acetyl-p53 (Lys 373), phospho-
p53 (Ser 15), and phospho-p53 (Ser 46) were acquired from
Cell Signaling Technology (Beverly, MA). Antip21 and an-
tip53 antibodies were purchased from BD Biosciences
Pharmingen (San Diego, CA) and Novocastra Laboratory.
Ltd. (United Kingdom), respectively, while those against
c-myc and -actin were acquired from Santa Cruz Biotech-
nology (Santa Cruz, CA). Negative control and p53-specific
small interfering RNA (siRNA) were purchased from Am-
bion (Austin, TX).
Treatment with HDACIs and IR
Cells were pretreated with SAHA (2.5M) or TSA
(0.5M). After 2 hours, cells were irradiated with various
doses of -IR using a 137Cs -ray source (Atomic Energy of
Canada Ltd., Canada).
Measurement of Cell Viability
Cell viability was determined by measuring the mi-
tochondrial conversion of 3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide (MTT) to a colored product.
Cells were treated with the specified drugs, and the me-
dium was exchanged with serum-free medium containing 1
mM MTT. After 4 hours of incubation at 37°C, cells were
solubilized in DMSO. The amount of formazan, the con-
verted form of MTT, was determined by measuring absor-
bance at 570 nm.
Analysis of Cellular Apoptosis
Apoptosis was determined using an annexin V-fluores-
cein isothiocyanate/propidium iodide (PI) kit (BD Pharmin-
gen, San Jose, CA). Briefly, cells were washed with cold
phosphate-buffered saline and resuspended in binding buffer
(10 mM HEPES, pH 7.4, 140 mM NaCl, and 2.5 mM CaCl2)
at a concentration of 1  106 cells/ml. Cells were incubated
with 5 l of Annexin V-fluorescein isothiocyanate and PI and
analyzed with a FACScan flow cytometer (Becton Dickinson,
San Jose, CA).
Measurement of Mitochondrial
Transmembrane Potential
Loss of mitochondrial transmembrane potential was mea-
sured using an ApoAlert mitochondrial membrane sensor kit
(Clontech, Palo Alto, CA), according to the manufacturer’s
instructions. Briefly, after drug treatment, cells were incu-
bated with Mitosensor for 15 minutes at 37°C. After centrif-
ugation at 1700 g for 7 minutes, cells were resuspended in
washing buffer and analyzed with the fluorescence channel
by flow cytometry. Results are presented as mean values of
the stained cell histogram.
Clonogenic Assay
Cells were seeded at a concentration of 200 cells per
60-mm dish and pretreated with 0.5 M or 1 M SAHA.
After 2 hours, cells were irradiated with various doses (1
or 2 Gy) of -IR. After culturing for 18 days, colonies
were stained with the Diff Quik kit (Sysmex, Japan), and
the number of colonies greater than 2 mm in diameter was
counted (300 colonies per well is a cutoff number of
colonies required for each treatment for a valid experi-
ment). The relative surviving fraction was calculated by
dividing the number of colonies of treated cells by that of
the control.
Western Blotting
Cells were harvested and lysed in radioimmunopre-
cipitation buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% Nonidet P40, 0.5% sodium deoxycholate, and 0.1%
sodium dodecyl sulfate supplemented with a protease in-
hibitor cocktail; Roche, Mannheim, Germany). Lysate
concentrations were determined with the Bradford assay.
Equal amounts of protein (20–50 g) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane. Membranes
were blocked with 3% skim milk in Tris-buffered saline
for 1 hour and incubated overnight with the relevant
primary antibodies (1000:1). Then, membranes were incu-
bated with horseradish peroxidase-conjugated secondary
antibody (3000:1) for 1 hour. Immunoreactive proteins
were visualized with the enhanced chemiluminescence
reagent (Amersham Biosciences, Little Chalfont, United
Kingdom).
Site-Directed Mutagenesis
The p53 mutant (C135Y and K382R) constructs were
generated using the Stratagene site-directed mutagenesis kit
(La Jolla, CA). Wild-type p53 expression vector (Invitrogen)
was used as the template. K382 of wild-type p53 was mutated
to arginine using the following primer sequences: p53-
K382R-up, 5-CT ACC TCC CGC CAT AAA AG(A)A CTC
ATG TTC AAG A-3 and p53-K382R-down, 5-T CTT GAA
CAT GAG TC(T)T TTT ATG GCG GGA GGT AG-3.13 For
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substitution of C135 of p53 with tyrosine, the following
primer sequences were used: p53-C135Y-up, 5-C CTC AAC
AAG ATG TTT TA(G)C CAA CTG GCC AAG ACC-3 and
p53-C135Y-down, 5-GGT CTT GGC CAG TTG GT(C)A
AAA CAT CTT GTT GAG G-3. The replaced nucleotides
within the sequences are italicized, and the original nucleo-
tides are presented in parentheses. The p53 6KR mutant
plasmids and primers were synthesized by Cosmogene Tech
(Seoul, South Korea).
Transfections
The c-myc-expressing plasmid was a kind gift from Dr.
Younghun Han (KIRAMS, Korea). A549 cells were trans-
fected with 0.2 to 0.6 g plasmid or 60 nM siRNA, using
Lipofectamine 2000 (Invitrogen), in 1 ml of serum-free
medium for 4 hours at 37°C in a CO2 incubator, according to
the manufacturer’s recommendations. Next, 2 ml of 10% fetal
bovine serum was added, followed by incubation for an
additional 3 hours. After transfection, cells were subjected to
apoptosis analysis, as described earlier.
RESULTS
Radiosensitization Effects of HDACIs
The effects of HDACIs, including SAHA and TSA,
in combination with IR, were examined in the human
non-small cell lung cancer cell line, A549. The MTT assay
was used to determine cell viability (Figure 1A). Our
results showed that a combination of HDACIs and IR
decreased the viability of cells more significantly than
either agent alone. Cell death analysis was additionally
performed on cells treated with HDACIs, IR, or both for 24
hours. Annexin V/PI staining experiments revealed that the
HDACI/IR combination synergistically induced cell death
(Figure 1B). Consistent with Annexin V/PI staining data,
HDACIs and IR exerted similar synergistic effects on loss
of mitochondrial transmembrane potential. These findings
clearly indicate that a combination of HDACIs and IR
triggers a higher degree of apoptosis in cells than either
agent alone. Next, A549 cells were exposed to IR in the
presence and absence of the HDACI, SAHA, and clono-
FIGURE 1. Combinations of suberoylanilide hydroxamic acid (SAHA) or trichostatin A (TSA) and irradiation exert synergistic
cytotoxic effects through mitochondrial injury. A, Cells were treated with 2.5 M SAHA, 0.5 M TSA, ionizing radiation (IR)
alone (5 and 10 Gy) or a combination of 2.5 M SAHA or 0.5 M TSA and IR for 24 hours. After treatment with MTT, data
were acquired as absorbance of solubilized formazan. The viability of control cells was set at 100%, and survival relative to the
control was calculated. **p  0.01 versus nontreated control groups. B, Cells were treated with 2.5 M SAHA or 0.5 M TSA,
either alone or combination with 10Gy IR, for 24 hours. Apoptosis was measured as the percentage of propidium iodide() or
Annexin V() cells, using flow cytometry. Mitochondrial transmembrane potential was analyzed by staining with Mitosensor,
followed by flow cytometry. **p  0.01 versus nontreated control groups. C, Cells were treated with SAHA and IR, either
alone or combination, at the indicated doses. After 18 days, colonies were stained with Diff Quick kit and counted. The rela-
tive surviving fractions were calculated by dividing the number of colonies of treated cells by that of the control. **p  0.01
versus nontreated control groups. Each value represents means  standard deviation of three independent experiments.
MMP, mitochondrial membrane potential; CTL, control.
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genic survival was determined. The radiation survival
curve showed that SAHA treatment sensitized the cells to
IR (Figure 1C). Notably, the radiation survival curve of
cells treated with 0.5 M SAHA diverged from that of
cells treated with 1 M SAHA. This effect was more
evident at higher radiation doses.
p53 Is Up-Regulated by the Combination of
HDACIs and IR
To explore the molecular mechanisms underlying the
combined effects of HDACIs and IR, we evaluated the p53,
phosphorylated p53 (phospho-p53, Ser 15, and 46), and
acetylated p53 (acetyl-p53, Lys 373, and 382) levels, after
cotreatment with HDACIs and IR or single agents. As shown
in Figure 2, p53 and phospho-p53 levels were markedly
increased in cells treated with IR in both the presence and
absence of HDACIs. Interestingly, the HDACI/IR combina-
tion further enhanced acetyl-p53 (Lys 382) and c-myc protein
levels, relative to either agent alone. In contrast, the level of
p53 acetylated at Lys 373 remained unchanged. The p21Waf1
protein was up-regulated to a similar extent in cells treated
with the HDACI/IR combination or either agent alone. Our
data suggest that HDACIs and IR act concertedly to modulate
the acetyl-p53 level to a greater extent, compared with either
agent alone.
Effects of p53 Down-Regulation on
Cell Viability
To further investigate the association between p53 and
the radiosensitizing effect of HDACIs, we examined the
effects of p53 siRNA in cells cotreated with SAHA and IR.
Transfection of A549 cells with p53-selective siRNA led to a
marked reduction in the p53 and p21 protein levels. Knock-
down of p53 with siRNA significantly attenuated the radio-
sensitization effect of SAHA, supporting the involvement of
p53 in this process (Figure 3A). Interestingly, c-myc expres-
sion was down-regulated on SAHA and IR cotreatment and
significantly recovered in the presence of p53 siRNA. Fur-
thermore, transfection of H1299 p53-null cells with a plasmid
expressing the p53 C135Y mutant led to recovery from cell
death and c-myc down-regulation induced by the combina-
tion of HDACIs and IR (Figure 3B). The p53 C135Y expres-
sion plasmid encoding a dominant-negative mutant can no
longer interact with p53 binding sites because of a confor-
mational change induced by mutation of cysteine 135 to
tyrosine.16,17 These results suggest that p53 plays an impor-
tant role in the radiosensitization effect of HDACIs and acts
upstream of c-myc expression.
Effects of c-Myc Overexpression on
Cell Viability
Because the combination of HDACIs and IR induced
p53-dependent repression of c-myc, we investigated whether
c-myc expression affected cell death in cotreated cultures.
After transient transfection with the pcDNA3 c-myc vector,
A549 cells were cotreated with HDACIs and IR (Figure 4).
Overexpression of c-myc partially blocked cell death induced
by HDACIs and IR. On the basis of these findings, we
propose that c-myc repression is involved in the radiosensi-
tizing effect of HDACIs.
Induction of p53 Acetylation-Mediated c-myc
Repression by the Combination of HDACIs
and IR
To confirm that c-myc-induced repression in cell death
induced by the combination of HDACIs and IR is regulated
by p53 acetylation, we performed experiments with the p53-
null lung cancer cell line, H1299. As shown in Figure 5A, the
c-myc expression level was not altered by HDACIs alone or
in combination with IR. Moreover, we did not observe a
radiosensitizing cell death effect on H1299 cells. To further
identify the specific lysine acetylation sites of p53 critical for
c-myc repression, plasmids expressing wild-type p53 and p53
mutated at lysines 320, 370, 372, 373, 381, and 382 to
arginine (6KR) or lysine 382 to arginine (K382R) were
transfected into H1299 cells. H1299 expressing the K382R
and 6KR p53 mutants recovered from cell death induced by
HDACIs and IR to similar extents (Figure 5B). In keeping
with this finding, c-myc down-regulation induced by the
combination of HDACIs and IR was rescued on mutation of
p53. These data imply that repression of c-myc is accompa-
nied by increased p53 acetylation, particularly at lysine 382,
leading to the combined radiosensitizing cell death effect of
HDACIs and IR.
DISCUSSION
HDACIs enhance the sensitivity of various cell lines to
IR or chemotherapeutics.4–8 In this study, we showed that
combinations of HDACIs (SAHA and TSA) and IR syner-
FIGURE 2. Protein levels of acetyl-p53 (Lys 382) are up-
regulated and c-myc down-regulated synergistically in A549
cells cotreated with suberoylanilide hydroxamic acid (SAHA)
or trichostatin A (TSA) and ionizing radiation (IR). Cells were
treated for 24 hours as specified in Figure 1B. Western blot-
ting was carried out, as described in Materials and Methods
section. Equal protein loading was confirmed by Western
blotting for -actin. Immunoblots are representative of at
least two independent experiments.
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gistically induced cell death through acetyl p53-mediated
repression of c-myc expression. Low concentrations of HDA-
CIs alone exerted a marginal effect on p53, including protein
level, phosphorylation, and acetylation, but specifically po-
tentiated p53 acetylation on cotreatment with IR. Stabiliza-
tion of p53 induced by combined treatment with HDACI and
IR may occur through acetylation. It is well known that
specific HAT and HDAC enzymes modulate the acetylation
status of p53. Because several lysine residues of the p53
C-terminal domain are also targets for mdm2-mediated ubiq-
uitination, acetylation of these sites leads to an increase in the
steady-state level of p53.18,19 Therefore, it is generally ac-
cepted that posttranslational modifications play an important
role in the stabilization and activation of p53. A recent study
additionally suggested that acetylation prevents down-regu-
lation of p53 function by blocking the recruitment of mdm2
and mdmx to p53-responsive promoters.20
p53 regulates the expression of a number of target
genes that contribute to cellular responses. The tumor sup-
pressor directly induces genes that promote apoptosis, such as
p21, bax, puma, noxa, and fas.21,22 In addition, p53 sup-
presses genes that inhibit p53-induced apoptosis, such as
bcl-2, survivin, and c-myc.23,24 Accordingly, we examined
whether the p53-regulated genes, bcl-2, bax, p21, and puma,
are involved in the radiosensitization effects of HDACIs. In
our experiments, Puma and c-myc protein levels were altered
on cotreatment with HDACIs and IR (Figure 2). Synergistic
induction of apoptosis by HDACIs and IR was not affected
on transfection of cells with siRNA against Puma (data not
shown), suggesting that Puma is not the critical cause of cell
death. Expression of c-myc protein was markedly decreased
after treatment with HDACIs and IR and recovered on trans-
fection with p53 siRNA (Figures 2 and 3). In addition,
ectopic expression of c-myc led to a significant decrease in
apoptotic cell death induced by HDACIs and IR (Figure 4).
These results indicate that c-myc expression is repressed
through p53 activation and that this step plays an important
role in apoptosis coinduced by HDACIs and IR.
c-Myc acts as a transcription activator or repressor that
regulates proliferation, mitogenesis, differentiation, and pro-
grammed cell death.23 A previous study showed that the
c-Myc interaction partner, Miz-1, binds and activates tran-
scription of the p21WAF1/CIP1 promoter, leading to inhibition
of cell cycle progression.25 In addition, it is reported that TSA
activates p21 expression through down-regulation of c-myc
and release of c-myc repression from the p21 promoter in
HeLa cells.1 To further ascertain whether down-regulation of
c-myc is mediated by p21, we examined the c-myc expres-
FIGURE 3. Suppression of p53 levels using small interfering RNA (siRNA) and inhibition of p53 binding activity with a p53
dominant-negative mutant rescues cells from suberoylanilide hydroxamic acid (SAHA) and ionizing radiation (IR) cotreatment-
induced cell death and restores c-Myc expression to a significant extent. A, A549 cells were transfected with 60 M p53-spe-
cific siRNA using the Lipofectamine kit. Cells transfected with control siRNA (si CTL) and p53 siRNA (si p53) were left un-
treated () or treated with () 2.5 M SAHA and 10Gy IR for 24 hours. After treatment with MTT, the viability of control
cells was set at 100%, and survival relative to the control was calculated. Cells were lysed and subjected to Western blot anal-
ysis using the p53 and c-Myc antibodies. Equal protein loading was confirmed by Western blotting for -actin. The specificity
of interference with target protein (p53) expression was confirmed by Western blotting for p21. *p  0.05 versus control
siRNA-transfected and IR/SAHA-treated groups. B, H1299 cells were transfected with 0.2 g mock vector (pCMV) or p53 wild-
type (p53) plasmid or p53 mutant C135Y plasmid (C135Y) and treated with 2.5 M SAHA and 5Gy IR. After treatment with
MTT, data were acquired as absorbance of solubilized formazan. The viability of control cells was set at 100%, and survival
relative to the control was presented. Cells were lysed and subjected to Western blot analysis using the p53 and c-Myc anti-
bodies. Interference with p53 binding activity was confirmed by Western blotting for p21. **p  0.01 versus the p53 plasmid-
transfected and IR/SAHA-treated groups. Data are presented as means  standard deviation of three independent experi-
ments. Immunoblots are representative of at least two independent experiments.
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sion levels in H1299 cells before and after combined treat-
ment with HDACIs and IR. As shown in Figure 5, the p21
level was up-regulated by SAHA alone and in combination
with IR in p53-null cells, whereas the c-myc level remained
unchanged. In addition, we observed no attenuation of the
p21 level after treatment with both HDACIs and IR in the
presence of specific siRNA against c-myc (data not shown).
On the basis of these results, we conclude that p53-dependent
repression of c-myc is not a consequence of p53-dependent
p21 activation.
Selective acetylation of p53 triggers differential
changes in gene expression.26 To identify the specific site of
p53 acetylation influencing c-myc repression on cotreatment
with HDACIs and IR, we transfected plasmids expressing
mutant p53 (6KR or K382R) into p53-null H1299 cells.
Expression of c-myc expression was recovered on transfec-
tion of cotreated cells with the p53 K382R mutant, suggesting
that repression of c-myc by p53 is mediated by acetylation at
K382 (Figure 5B). Binding of p53 to the c-myc promoter may
be decreased as a result of acetylation. Further studies are
necessary to determine the mechanism by which p53 acety-
lated at K382 regulates c-myc expression, and whether other
acetylation site(s) of p53 are involved in this process. In
FIGURE 4. c-Myc overexpression partially blocks cell death
induced by the combination of suberoylanilide hydroxamic
acid (SAHA) and ionizing radiation (IR). Cells were transiently
transfected with the control plasmid (pcDNA) and plasmid
encoding c-Myc (c-Myc). After transfection, cells were
treated with 2.5 M SAHA and 10 Gy IR () or 0.5 M tri-
chostatin A (TSA) and 10 Gy IR (*) for 24 hours. After treat-
ment with MTT, data were acquired as absorbance of solubi-
lized formazan. The viability of control cells was set at
100%, and survival relative to the control was calculated.
Cells were lysed and subjected to Western blot analysis.
Overexpression and equal protein loading were confirmed
by Western blotting for c-myc and -actin, respectively.
*p  0.05 versus pcDNA (mock)-transfected and SAHA/
IR-treated or TSA/IR-treated groups, respectively. Data are
presented as means  SD of three independent experi-
ments. Immunoblots are representative of at least two inde-
pendent experiments.
FIGURE 5. c-Myc protein levels are not altered in p53 mu-
tant-transfected H1299 cells cotreated with histone deacety-
lase inhibitors and ionizing radiation (IR). Acetylation of p53
at K382 is required for down-regulation of c-myc. A, H1299
cells were treated for 24 hours as specified in Figure 1B and
subjected to Western blot analysis. Equal protein loading
was confirmed by Western blotting for -actin. B, H1299
cells were transiently transfected with the control plasmid
(pCMV) and plasmid encoding wild-type, K382R, or 6KR
mutant p53 (p53, K382R, and 6KR, respectively), followed
by treatment with 2.5 M suberoylanilide hydroxamic acid
(SAHA) and 5Gy IR for 24 hours. After treatment with MTT,
the viability of control cells was set at 100%, and survival
relative to the control was calculated. Cells were lysed and
subjected to Western blot analysis. Equal protein loading
was confirmed by Western blotting for -actin. **p  0.01
versus p53 plasmid-transfected and IR/SAHA-treated groups.
Each value represents means  SD of three independent ex-
periments. Immunoblots are representative of at least two
independent experiments. TSA, trichostatin A.
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conclusion, our data strongly suggest that radiosensitizing
effect of HDACIs is mediated by c-myc repression dependent
on p53 acetylation at K382.
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